NCT03572153

Brief Summary

The long-term goal of this program of research is to determine safe and effective non-hormonal interventions for menopausal symptoms. The main goal of this study is to evaluate whether self-administered hypnosis can be used to significantly reduce hot flashes more than self-administered white noise hypnosis over 6 weeks of home practice. The investigators are also examining the impact of each hypnosis group on sleep, anxiety, perceived and measured stress, heart rate variability, and daily activities.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 28, 2018

Completed
8 months until next milestone

Study Start

First participant enrolled

March 4, 2019

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 16, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 16, 2024

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

June 5, 2025

Completed
Last Updated

June 5, 2025

Status Verified

May 1, 2025

Enrollment Period

5 years

First QC Date

June 17, 2018

Results QC Date

March 27, 2025

Last Update Submit

May 19, 2025

Conditions

Keywords

Hot FlashesPostmenopausal SymptomsHypnotic Relaxation TherapyMind BodyHypnosis

Outcome Measures

Primary Outcomes (1)

  • Hot Flash Daily Diary

    Participants completed the Hot Flash Daily Diary (Sloan et al., 2001) every day for 6 weeks to measure the daily frequency and severity (mild, moderate, severe, and very severe) of hot flashes. A total hot flash score was calculated for each participant (product of frequency x severity) after severity ratings were assigned a point value as follows: * mild = 1 * moderate = 2 * severe = 3 * very severe = 4 The hot flash score was then calculated by multiplying the participants' frequency and severity ratings of hot flashes, divided by the total number of days. A lower score indicates less frequent and/or severe hot flashes.

    The hot flash daily diary was collected at baseline (week 0), endpoint (week 6) and follow-up (week 12).

Secondary Outcomes (5)

  • Hot Flash Related Daily Interference Scale

    The Hot Flash Related Daily Interference Scale was completed at Baseline (week 0), at endpoint (week 6) and at follow-up (week 12).

  • Emotional Distress Anxiety Scale

    Baseline, 6 & 12 Weeks

  • Pittsburgh Sleep Quality Index

    Baseline, 6, & 12 weeks.

  • Subject Global Impression of Change

    The Subject Global Impressions of Change will be completed only at 6 weeks.

  • Perceived Stress Scale

    Baseline, 6, & 12 weeks

Other Outcomes (1)

  • Self-Hypnosis Practice Log

    The practice log was completed daily by the participants and submitted to the interventionists at the end of each week throughout the study's duration (weeks one through six) and at follow-up (week 12)."

Study Arms (2)

Self-Administered Hypnosis

EXPERIMENTAL

Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.

Behavioral: Self-Administered Hypnosis

Self-Administered White Noise Hypnosis

ACTIVE COMPARATOR

Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.

Behavioral: Self-Administered White Noise Hypnosis

Interventions

Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.

Self-Administered Hypnosis

Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.

Self-Administered White Noise Hypnosis

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Postmenopausal as defined by one of the following criteria:
  • No menstrual period in the past 12 months
  • Chemical menopause (LHRH antagonists)
  • Surgical Menopause (bilateral oophorectomy)
  • Evidence of menopause status per FSH and estradiol levels per institutional guidelines. Self-reported history of a minimum of 4 hot flashes per day or 28 hot flashes per week at baseline.
  • Age over 18 years and able to give consent for participation in the study.
  • Have discontinued other putative therapies for hot flashes for at least one month prior to enrollment (Vitamin E will be allowed)
  • Women with a diagnosis of DCIS or invasive breast cancer stages 0-III are allowed to participate and may be on endocrine therapy of any kind. If on endocrine therapy, women must be on it for 4 weeks and not expected to stop it during the study. If not on endocrine therapy, participants should not be planning to start during the course of the study. However, unexpected treatment will not require study withdrawal but will be recorded and considered in the analysis.

You may not qualify if:

  • Currently receiving other simultaneous treatment for hot flashes (antidepressant use is allowed if being used for mood alterations and participant has been on the antidepressant for at least 3 months with no plans to change dose or antidepressant during this study)
  • Diagnosis of clinical depression or acute anxiety disorder
  • Diagnosis of a serious psychological illness, specifically psychoses, schizophrenia or borderline personality disorder
  • Currently using hypnosis for any reason
  • PHQ-4 score ≥ 9
  • Non-English speaking
  • Women with stage IV breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Baylor University

Waco, Texas, 76798, United States

Location

Related Publications (1)

  • Elkins G, Arring N, Morgan G, Lorenz T, Muniz V, Lafferty C, Scheffrahn K, Alldredge C, Barton D. Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes: A Randomized Clinical Trial. JAMA Netw Open. 2025 Nov 3;8(11):e2542537. doi: 10.1001/jamanetworkopen.2025.42537.

MeSH Terms

Conditions

Hot FlashesBreast Neoplasms

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Results Point of Contact

Title
Gary Elkins, PhD
Organization
Baylor University

Study Officials

  • Gary Elkins, Ph.D.

    Baylor University

    PRINCIPAL INVESTIGATOR
  • Debra Barton, RN,PhD,FAAN

    University of Michigan

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Participants will be randomized and either be assigned to the self-hypnosis group or a self-administered white noise hypnosis group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Mind-Body Medicine Research Lab

Study Record Dates

First Submitted

June 17, 2018

First Posted

June 28, 2018

Study Start

March 4, 2019

Primary Completion

February 16, 2024

Study Completion

February 16, 2024

Last Updated

June 5, 2025

Results First Posted

June 5, 2025

Record last verified: 2025-05

Locations